Literature DB >> 3139428

Haemodynamic, anti-anginal and anti-ischaemic effects of sublingual nitroglycerin: dose-response, duration and time of onset of action.

G Nyberg1, B Holmberg.   

Abstract

To establish the time of onset of action and magnitude of response to the quickest disintegrating sublingual nitroglycerin tablet available in Scandinavia (Nitromex), nine patients with stable exercise-induced angina were studied whilst performing bicycle exercise tests. In the first session, placebo, 0.25, 0.50 and 0.75 mg sublingual nitroglycerin (Nitromex) was given in a double-blind cross-over fashion on different days. In the second session (1 h after Session 1), nitroglycerin 0.5 mg (Nitromex), placebo and 0.5 mg of a different brand of nitroglycerin were compared for the time of onset of attenuation of ST-segment depression when administered during exercise. In Session 1, there was a dose-dependent fall in systolic blood pressure and a concordant rise in heart rate whilst sitting at rest prior to exercise. Exercise time and ST-segment depression were dose-dependently prolonged, significantly by the two higher doses, (mean 20 and 26%, respectively) which did not differ from one another. In Session 2, nitroglycerin (Nitromex) caused ST-segment reversal after a mean of 123 s after administration, which was shorter than after ordinary nitroglycerin (mean 157 s) and placebo (two tests, 186 and 192 s). It is suggested that when nitroglycerin is administered during exercise, chest pain and ischaemic ECG-changes are largely improved through coronary vasodilatation and reduced afterload rather than through increased venous pooling and reduction in preload.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139428     DOI: 10.1007/bf00615218

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin.

Authors:  J E Gage; O M Hess; T Murakami; M Ritter; J Grimm; H P Krayenbuehl
Journal:  Circulation       Date:  1986-05       Impact factor: 29.690

2.  Rate of onset of vasodilator effect of glyceryl trinitrate, propatylnitrate and erythrityl tetranitrate in man.

Authors:  G Johnsson; M Henning; B Ablad
Journal:  Scand J Clin Lab Invest       Date:  1965       Impact factor: 1.713

3.  Antianginal effects of nitroglycerin during exercise-induced angina: hemodynamic and left ventricular function changes related to indexes of myocardial oxygen consumption.

Authors:  C Y Choong; G S Roubin; G J Bautovich; P J Harris; D T Kelly
Journal:  Am J Cardiol       Date:  1987-11-16       Impact factor: 2.778

4.  Effect of nitroglycerin ointment (Nitrong) on exercise tolerance and several circulatory parameters in patients with angina pectoris.

Authors:  G Nyberg; V Panfilov
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  [Changes of regional blood volume after the application of nitroglycerin measured by functional whole-body scanning (author's transl)].

Authors:  W Schörner; M Schartl; R Felix
Journal:  Z Kardiol       Date:  1982-01

6.  Incomplete and delayed bioavailability of sublingual nitroglycerin.

Authors:  P K Noonan; L Z Benet
Journal:  Am J Cardiol       Date:  1985-01-01       Impact factor: 2.778

7.  Rapidity of the hypotensive effect of short-acting nitrous compounds.

Authors:  J Heikkilä; M H Frick
Journal:  Ann Clin Res       Date:  1969-12

8.  The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of the drug response.

Authors:  B G Brown; E Bolson; R B Petersen; C D Pierce; H T Dodge
Journal:  Circulation       Date:  1981-12       Impact factor: 29.690

9.  Effect of beta-adrenergic blockade on haemodynamic responses to dynamic and isometric exercise in angina pectoris.

Authors:  G Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1979-07       Impact factor: 2.953

10.  Relation between ST-depression and chest pain in patients with coronary heart disease receiving no treatment and after beta-blockade and combined alpha-beta-blockade.

Authors:  G Nyberg; T Bjurö; M Hagman; U Smith
Journal:  Acta Med Scand Suppl       Date:  1981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.